Antibody-drug conjugates in breast cancer:advances and prospects  

作　　者：Zhiqiang Shi Yongjin Lu Qiuchen Zhao Yongsheng Wang Pengfei Qiu 

机构地区：[1]Breast Cancer Center,Shandong Cancer Hospital and Institute,Shandong First Medical University and Shandong Academy of Medical Sciences,Jinan 250117,China [2]Tianjin Medical University Cancer Institute&Hospital,National Clinical Research Center for Cancer,Tianjin 300202,China [3]Shandong First Medical University(Shandong Academy of Medical Sciences),Jinan 271016,China [4]Cancer Research UK Cambridge Centre PhD Programme,University of Cambridge,Cambridge CB20XZ,UK

出　　处：《Cancer Biology & Medicine》2025年第2期83-92,共10页癌症生物学与医学(英文版)

基　　金：supported by grants from the National Natural Science Foundation of China(Grant No.81672638)。

摘　　要：The“Global Cancer Statistics Report 2022”estimates that there were approximately 20 million new cancer cases worldwide,including 9.7 million in females,of which 2.31 million were breast cancer cases1.Breast cancer is the most common malignant tumor in women and one of the leading causes of cancer-related deaths.

关 键 词：cancer related deaths breast cancer malignant tumor antibody drug conjugates global cancer statistics report 

分 类 号：R737.9[医药卫生—肿瘤]